EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY-NC-ND 4.0

Diagnostic efficacy of blood biomarkers for differentiating early-stage pancreatic cancer from chronic pancreatitis: A systematic review and network meta-analysis

Di Wu, Zeng-Kan Du, Yuan-Chen Wang, Yi-Zhou Zheng, Hang-Ming Qi, Yu-Ru-Chen Zhu, Yu Cao, Lei Wang, Wen-Bin Zou, Zhuan Liao

Translational Oncology · 2026-03 · 65 · 102674

DOI: 10.1016/j.tranon.2026.102674 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Translational Oncology, 2026-03. Verfasst von Di Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, National Clinical Research Center for Digestive Diseases, Changhai Hospital, Naval Medical University, 168 Changhai R…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, National Key Research and Development Program of China Stem Cell and Translational Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

• Carbohydrate antigen 19–9 (CA199) demonstrated only moderate diagnostic discrimination between pancreatic cancer (PC) and chronic pancreatitis (CP), with reduced efficacy in early-stage PC. • Tumor polypeptide antigen (TPA), microRNAs, extracellular vesicle long RNAs (exLRs), metabolites panel, and carcinoembryonic antigen (CEA) showed unique strengths in their diagnostic ability. • The application of multi-marker panels, particularly those that incorporate miRNAs and exLRs, for early detection of PC in CP holds significant clinical value for improving patient management. Early diagnosis of pancreatic cancer (PC) remains challenging, particularly in patients with chronic pancreatitis (CP). Currently, imaging is often inaccurate and biopsy is inherently invasive. This is the first network meta-analysis (NMA) comparing blood-based biomarkers for differentiating PC from CP. PubMed and EMBASE were searched for studies evaluating blood-based biomarkers for distinguishing PC from CP. Risk of bias was assessed with QUADAS-2. We conducted individual biomarker meta-analysis with generalized bivariate models. For the NMA, we applied a Bayesian inference approach via a Markov-chain Monte Carlo random effects model. The surface under the cumulative ranking curve was used to rank the diagnostic performance of the biomarkers. Across 139 enrolled studies, 49 biomarkers or panels were analyzed. For differentiating PC from CP, tumor polypeptide antigen (TPA) had the highest area under the summary receiver operating characteristic curve (AUSROC) (0.92). The NMA revealed that microRNA-196b (miR-196b) ranked highest in sensitivity (OR 3.74e+27), while the combination of carbohydrate antigen 19–9 (CA199) and a panel of eight extracellular vesicle long RNAs (exLRs) exhibited the highest specificity (OR 3.78). For early-stage (stage I and II) PC, the eight exLRs showed the highest relative sensitivity (OR 7.00), and carcinoembryonic antigen (CEA) demonstrated the highest specificity (OR 4.70). CA199 demonstrated only moderate diagnostic discrimination between PC and CP, with reduced efficacy in early-stage PC. Combining CA199 and eight exLRs exhibited promising differential diagnostic efficacy with both high sensitivity and specificity.

Schlagwörter

Stichwörter der Autor:innen

Blood-based biomarkersChronic pancreatitisDiagnostic testsNetwork meta-analysisPancreatic cancer

Autor:innen und Institutionen

  • Department of Gastroenterology, National Clinical Research Center for Digestive Diseases, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai 200433, China; Shanghai Institute of Pancreatic Diseases…
  • Department of Gastroenterology, National Clinical Research Center for Digestive Diseases, Changhai Hospital, Naval Medical University, 168 Changhai Road, Shanghai 200433, China.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • National Key Research and Development Program of China Stem Cell and Translational Research

Zitieren

APA

Wu, D., Du, Z. K., Wang, Y. C., Zheng, Y. Z., Qi, H. M., Zhu, Y. R., Cao, Y., Wang, L., Zou, W. B., & Liao, Z. (2026). Diagnostic efficacy of blood biomarkers for differentiating early-stage pancreatic cancer from chronic pancreatitis: A systematic review and network meta-analysis. Translational Oncology, 65, 102674. https://doi.org/10.1016/j.tranon.2026.102674

Vancouver

Wu D, Du ZK, Wang YC, Zheng YZ, Qi HM, Zhu YR, et al. Diagnostic efficacy of blood biomarkers for differentiating early-stage pancreatic cancer from chronic pancreatitis: A systematic review and network meta-analysis. Translational Oncology. 2026;65:102674. doi:10.1016/j.tranon.2026.102674

BibTeX
@article{Wu2026,
  author = {Wu, Di and Du, Zeng-Kan and Wang, Yuan-Chen and Zheng, Yi-Zhou and Qi, Hang-Ming and Zhu, Yu-Ru-Chen and Cao, Yu and Wang, Lei and Zou, Wen-Bin and Liao, Zhuan},
  title = {Diagnostic efficacy of blood biomarkers for differentiating early-stage pancreatic cancer from chronic pancreatitis: A systematic review and network meta-analysis},
  journal = {Translational Oncology},
  year = {2026},
  volume = {65},
  pages = {102674},
  doi = {10.1016/j.tranon.2026.102674}
}
Kostenlos starten →